. 2023 Aug 2;12(9):e230059. doi: 10.1530/EC-23-0059
This work is licensed under a Table 2.
Characteristics of 41 patients with PAI enrolled into the study, stratified for patients’ adherence.
| Adherent (n = 28) | Non-adherent (n = 13) | |
|---|---|---|
| Age (years) | 49 (32–66) | 29 (25–33)a |
| Male % (n) | 57 (16) | 69 (9) |
| Female % (n) | 43 (12) | 31 (4) |
| Total daily MC dose (μg/day) | 100 (50–150) | 200 (150–200)a |
| Patients with SW-CAH, % (n) | 25 (7) | 77 (10) |
| Patients with AD, % (n) | 75 (21) | 23 (3) |
| Total daily GC dose (mg/day, HCeq) | 22.5 (18–30) | 25 (23–36)a |
| Hydrocortisone % (n) | 82 (23) | 31 (4) |
| Prednisolone % (n) | 18 (5) | 69 (9) |
| BMI (kg/m²) | 25.7 (21.8–30.3) | 27.0 (20.8–31.9) |
| SBP (mmHg) | 120 ± 17 | 119 ± 12 |
| DBP (mmHg) | 74 ± 9 | 67 ± 8 |
| MAP (mmHg) | 89 ± 10 | 84 ± 9 |
| Na⁺ (mmol/L) | 140 (138–142) | 140 (139–142) |
| K⁺ (mmol/L) | 4.3 (3.7–4.8) | 3.6 (3.4–4.0)a |
| PRC (μIU/mL) | 107.3 (36.4–315.3) | 164.6 (95.0–313.7) |
| 17-OH-progesterone (nmol/L)b | 2.0 (1.0–90.0) | 55.0 (35.6–119.0) |
| Androstenedione (nmol/L)b | 2.4 (1.0–14.9) | 13.3 (9.8–34.43) |
| sFC (pg/mL) | 25.1 (10.8–50.7) | 34.2 (27.9–44.4) |
| uFC (pg/mL) | 115.0 (35.9–256.7) | 163.0 (56.3–245) |
Data are shown as mean ± s.d. or median (IQR) as appropriate for distribution of data.
a P < 0.05 vs adherent; bOnly patients with CAH (n = 17).
AD, Addison’s disease; BMI, body mass index; DBP, diastolic blood pressure; GC, glucocorticoid; HCeq, equivalent dose of hydrocortisone; K+, potassium levels; MAP, mean arterial pressure; MC, mineralocorticoid; Na+, sodium levels; PRC, plasma renin concentration; SBP, systolic blood pressure; sFC, serum fludrocortisone levels; SW-CAH, salt-wasting congenital adrenal hyperplasia; uFC, urinary fludrocortisone levels.